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Correspondence
Ideology over evidence?
In her narrative, Dr Moncrieﬀ makes assertions about depres-
sive illness, antidepressants, and psychotropic medications.1
Her main points are that these medications are not clinically
eﬀective when using rating scales, and that the models pro-
posed for antidepressant action are erroneous. We would
suggest that the narrative reﬂects ideology, as opposed to
evidence, and should be interpreted accordingly.
First, a 1969 narrative supplementary review is given as an
example of the lack of eﬃcacy of tricyclic and older antide-
pressants. A more recent (and comprehensive) review found
signiﬁcant beneﬁts for monoamine oxidase inhibitors over
placebo, which were surpassed by tricyclics.2 The argument is
then made that changes on the Hamilton Rating Scale for
Depression (HRSD) are minimal, in comparison with placebo,
and that diﬀerences are clinically insigniﬁcant when the Clinical
Global Impression (CGI) scale is used, citing among other
reviews the Kirsch meta-analysis (where the eﬀect size was
0.313). A similar eﬀect size was seen in a recent analysis of
over 500 studies, which reported odds ratios of between 1.37
and 2.13 for response compared with placebo.4
In focusing the argument on change in total HRSD score,
Dr Moncrieﬀ appears unaware that the scale was never
intended to measure change. A more robust way of analysing it
was recently demonstrated, using the rating of subjective mood
(item 1 on the HRSD), which would be akin to the CGI. This
avoided the inﬂuence of antidepressant side-eﬀects on the
scale, and found clear beneﬁts for paroxetine and citalopram
over placebo.5
A study cited to indicate severity of depression did not
predict outcome, evaluated the short-term eﬃcacy of antide-
pressants and was not intended to test the hypothesis of
severity, with the authors reporting signiﬁcant beneﬁts of ﬂu-
oxetine over placebo in adults (improvement of approximately
35%).6 The 1964 Medical Research Council trial (which
showed the eﬃcacy of electroconvulsive therapy) is given as
evidence of lack of eﬀect of severity on response; however, the
statement that antidepressants did not outperform placebo is
not surprising, given that the dose of imipramine was 50 mg
and that of phenelzine 15 mg. A more recent and inﬂuential
publicly funded study (cited over 3000 times in Google
Scholar) showed the eﬀectiveness of imipramine (at a
therapeutic dose of around 185 mg) in people with severe
depression, in comparison with psychological therapies
(cognitive–behavioural therapy and interpersonal therapy).
These therapies showed little beneﬁt over placebo in this
group.7
The rest of the narrative dwells on ‘disease-centred’
models of psychiatric illness, as an alternative to the current
‘targeting a brain abnormality’ approach. We are unaware of
modern psychiatry relying on the neurotransmitter models she
discusses; the ﬁeld has moved on signiﬁcantly, and most neu-
roscientists would point to more nuanced models involving
eﬀects on neural networks and plasticity.8 The predominant
references cited here are Dr Moncrieﬀ’s own hypotheses.
In summary, we would suggest that Dr Moncrieﬀ’s nar-
rative is selective at best, and on cursory examination there is
little eﬀort to appraise the literature in a scientiﬁcally objective
manner. One cannot help but assume that this opinion piece
represents ideology over evidence, and therefore any inter-
pretation should be cautious.
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Rational antidepressant use
In her contribution to the ‘Against the Stream’ series,
Dr Moncrieﬀ1 articulates the case for the drug-centred model
of antidepressant action. She notes that antidepressants do not
typically outperform placebo in well-designed studies (par-
ticularly in rare instances where an active placebo is used as a
control2), have little clinical eﬀect and can cause serious
adverse eﬀects. Having made the case that antidepressants are
not ‘speciﬁc’ antidepressant agents, she makes some com-
ments about their use in clinical practice. I would like to oﬀer a
few remarks about these issues, including some musings about
what ‘rational antidepressant use’ might look like.
Modern psychiatric practice has seen the rise and fall of
several promising antidepressant agents (the monoamine oxi-
dase inhibitors, the tricyclic antidepressants and selective sero-
tonin reuptake inhibitors (SSRIs)). Recent eﬀorts include testing
the possible antidepressant properties of ketamine. But are these
eﬀorts futile? Perhaps yes, perhaps no. A truly speciﬁc anti-
depressant drug (if one is ontologically possible) appears to be a
pipedream, given current diagnostic limitations. Our categor-
isation of major depressive disorder is highly heterogeneous,3
creating a disjunctive category of cognitive, behavioural and
biological symptoms that do not reliably cluster together. Even if
any of our current drugs had speciﬁcity for ‘depression’, this
would be extremely diﬃcult to uncover in clinical practice or
research settings. As a result, drug development will be prone to
ideological, as opposed to scientiﬁc, revolutions.4
Should we therefore abandon antidepressants as a treat-
ment modality? As long as we are honest with our patients
about our current state of knowledge, I think not. Drug use has
always been an integral part of human life,5 helping to alleviate
life’s various physical, emotional and existential pains.
Antidepressants are no diﬀerent in this respect. While
researchers continue the search for a discrete condition called
‘depression’, drugs such as the SSRIs can be exploited for
particular patient complaints. Antidepressants can cause
emotional blunting, sedation, activation and decreased libido,
among other things. Some have a proclivity towards one eﬀect
more than others. These eﬀects can be exploited to relieve
particular problems (e.g. sedation to alleviate insomnia, or
emotional numbing to transcend an episode of intense anxiety
or distress), without pretence towards a yet-to-be discovered
condition. A rational provider would match a drug’s eﬀects to
the patient’s complaints, irrespective of diagnosis (or drug
class); and would remain vigilant to the development of any
adverse eﬀects or deterioration of condition, start at the lowest
recommended dose, and withdraw the patient from the drug as
soon as possible. Psychosocial interventions can remain an
important part of treatment, in many cases being the ﬁrst
treatment of choice. Antidepressants, like all drugs, are neither
angels nor demons. They should be used selectively and
thoughtfully, when used at all.
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Author’s reply: In response to Dr Jauhar and Professor Young, I
am used to being accused of using ideology, of being selective,
of not being balanced or of being polemical. I take no personal
oﬀence, but it is important to point out that this is a useful
tactic if you want to shut down debate. It harnesses the
authority of science to present one view as neutral, objective
and credible, and the other as self-interested and unreliable. In
truth, we all bring assumptions and biases to our work. I am
obviously unable to describe every study ever done on anti-
depressants in a short article, but I have written books and
papers that address all the evidence I could ﬁnd that supports
the disease-centred model of drug action in relation to anti-
depressants and other psychiatric drugs.1
Indeed, one of the most important points I am making in
relation to drug action is that existing psychopharmacological
research is based on unexamined assumptions about how
drugs work. These consist of the idea that drugs target the
neurological mechanisms underlying symptoms, whether the
latest theory about mechanisms concerns abnormalities of
neurotransmitters, neural networks or neuro-plasticity. This
idea has allowed psychopharmacology research to ignore the
alterations to normal functioning that psychiatric drugs pro-
duce, and that will aﬀect mental states including mental dis-
orders, regardless of the underlying mechanisms.
Jauhar and Young point out that the latest meta-analysis of
antidepressant trials ﬁnds impressive odds ratios for eﬀects of
antidepressants, but it analyses categorical outcomes derived
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